# Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

> **NCT01350115** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Basal Cell Carcinoma
- Gorlin Syndrome
- Nevoid Basal Cell Carcinoma Syndrome

## Interventions

- **DRUG:** LDE225
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01350115
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01350115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01350115, "Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01350115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*